CLAIMS

1. ~~A method of~~ Use of fitusiran in the manufacture of a medicament for improving joint function in a hemophilia patient, ~~comprising subcutaneously administering fitusiran~~wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

2. The ~~method of~~use according to claim 1, wherein ~~the administering~~administration of the medicament reduces difficulty in walking or increases mobility.

3. ~~A method of~~ Use of fitusiran in the manufacture of a medicament for improving a joint symptom in a hemophilia patient, ~~comprising subcutaneously administering fitusiran~~wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, wherein the joint symptom is selected from joint swelling, painful movement, and joint pain, and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

4. ~~A method of~~ Use of fitusiran in the manufacture of a medicament for improving patient-reported outcome (PRO) in a hemophilia patient, ~~comprising subcutaneously administering fitusiran~~wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors and optionally wherein the PRO is improved in one or more quality-of-life domains.

5. ~~A method of~~ Use of fitusiran in the manufacture of a medicament for improving quality of life (QoL) in a hemophilia patient, ~~comprising subcutaneously administering fitusiran~~wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, wherein the QoL is improved in one or more QoL domains and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

6. The ~~method of~~use according to any one of claims 1-5, wherein ~~fitusiran is administered at~~the medicament is suitable for administration at a dose of 40-90 mg ~~per dose~~of fitusiran.

7. The ~~method of~~use according to claim 4 or 5, wherein the one or more QoL domains are domains in a QoL questionnaire, optionally wherein the QoL questionnaire is Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).

8. The ~~method of~~use according to claim 7, wherein the ~~administering~~administration results in a clinically meaningful improvement indicated by a reduction of 7 or more units (optionally 8 or more, 9 or more, or 10 or more units) in one or more of Total Score, Sports and Leisure domain score, and Physical Health domain score of the Questionnaire.

9. The ~~method of~~use according to any one of claims 1-8, wherein the patient is an adult or adolescent patient twelve years or older with hemophilia A or B with or without inhibitors.

10. The ~~method of~~use according to any one of claims 1-9, wherein the patient has hemophilia A.

11. The ~~method of~~use according to claim 10, wherein the patient has been treated with factor VIII or a bypassing agent (BPA).

12. The ~~method of~~use according to claim 11, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

13. The ~~method of~~use according to claim 10 or 11, wherein the patient is without inhibitors.

14. The ~~method of~~use according to any one of claims 1-9, wherein the patient has hemophilia B.

15. The ~~method of~~use according to claim 14, wherein the patient has been treated with factor IX or a BPA.

16. The ~~method of~~use according to claim 15, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

17. The ~~method of~~use according to claim 14 or 15, wherein the patient is without inhibitors.

18. The ~~method of~~use according to any one of claims 11-13 or 15-17, wherein the BPA is activated prothrombin complex concentrates (aPCC) and/or recombinant activated Factor VII (rFVIIa).

19. The ~~method of~~use according to any one of claims 1-18, ~~comprising administering to~~wherein the patient is to be administered a plurality of doses of ~~fitusiran at~~the medicament, and wherein each dose of the medicament comprises about 50 mg ~~per dose~~of fitusiran.

20. The ~~method~~use according to of any one of claims 1-18, ~~comprising administering to~~wherein the patient is to be administered a plurality of doses of ~~fitusiran at~~the medicament, and wherein each dose of the medicament comprises about 80 mg ~~per dose~~of fitusiran.

21. The ~~method of~~use according to any one of claims 1-20, wherein the medicament comprises fitusiran ~~is provided~~ at a concentration of about 50-200 mg/mL, or optionally at a concentration of about 100 mg/mL, in a phosphate-buffered saline (pH 7).

22. The ~~method of~~use according to any one of claims 1-21, wherein ~~fitusiran is administered~~the medicament is suitable for administration to the patient about once every four weeks or about once a month.

~~23. Fitusiran for use in the method of any one of claims 1-22.~~

~~24~~23. ~~An article of manufacture for use in the method of~~administration of a medicament ~~according to any one of claims 1-22.~~

2524. The article of manufacture for use of claim 2423, wherein the article of manufacture is a single-use vial containing 80 mg of fitusiran in 0.8 mL of a phosphate-buffered saline (pH 7).

2625. The article of manufacture for use of claim 2423, wherein the article of manufacture is a single-use prefilled syringe containing 80 mg of fitusiran in 0.8 mL of a phosphate-buffered saline (pH 7).

2726. The article of manufacture for use of claim 2423, wherein the article of manufacture is a single-use vial containing 50 mg of fitusiran in 0.5 mL of a phosphate-buffered saline (pH 7).

2827. The article of manufacture for use of claim 2423, wherein the article of manufacture is a single-use prefilled syringe containing 50 mg of fitusiran in 0.5 mL of a phosphate-buffered saline (pH 7).

29. Use of fitusiran for the manufacture of a medicament to treat hemophilia A or B in the method of any one of claims 1-22.